Company intelligence / Profile preview
ONL Therapeutics
Ann Arbor, Michigan, United Statesonltherapeutics.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
ONL Therapeutics has demonstrated in clinical trials that its lead candidate, ONL1204 Ophthalmic Solution—a first-in-class small peptide Fas inhibitor—can reduce the rate of growth of geographic atrophy lesions in AMD patients and shows promise in protecting retinal cells from death and inflammation. The compound has orphan drug designation for retinal detachment. A consistent treatment effect was observed in early clinical studies comparing treated versus untreated eyes.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small peptides (specifically a Fas inhibitor peptide)Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Johnson & Johnson’s Specialty Ophthalmology R&D team provides input to ongoing clinical development plans.
Beyond the preview
Go deeper on ONL Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ONL Therapeutics.